1. Home
  2. CYPH vs BTMD Comparison

CYPH vs BTMD Comparison

Compare CYPH & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYPH

Cypherpunk Technologies Inc.

N/A

Current Price

$0.76

Market Cap

73.4M

Sector

Health Care

ML Signal

N/A

Logo Biote Corp.

BTMD

Biote Corp.

HOLD

Current Price

$2.27

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYPH
BTMD
Founded
2011
2012
Country
United States
United States
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.4M
71.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CYPH
BTMD
Price
$0.76
$2.27
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.83
AVG Volume (30 Days)
6.8M
191.0K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
722.22
EPS
N/A
0.06
Revenue
N/A
$192,219,000.00
Revenue This Year
N/A
$2.03
Revenue Next Year
N/A
$6.58
P/E Ratio
N/A
$37.67
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$1.27
52 Week High
$3.70
$4.75

Technical Indicators

Market Signals
Indicator
CYPH
BTMD
Relative Strength Index (RSI) 43.75 53.96
Support Level $0.54 $1.97
Resistance Level $0.79 $2.37
Average True Range (ATR) 0.11 0.16
MACD -0.02 -0.00
Stochastic Oscillator 31.82 58.41

Price Performance

Historical Comparison
CYPH
BTMD

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

About BTMD Biote Corp.

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

Share on Social Networks: